{"id":"tremelimumab-anti-ctla4","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Rash"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to CTLA-4, tremelimumab prevents the receptor from downregulating T-cell activation, leading to increased immune response against cancer cells. This mechanism is thought to be particularly effective in tumors with high PD-L1 expression.","oneSentence":"Tremelimumab is an anti-CTLA4 monoclonal antibody that blocks the CTLA-4 receptor, enhancing T-cell activation and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:31.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT03606967","phase":"PHASE2","title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma","enrollment":70},{"nctId":"NCT04034927","phase":"PHASE2","title":"Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-04","conditions":"Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor","enrollment":61},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT02888743","phase":"PHASE2","title":"Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-14","conditions":"Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":110},{"nctId":"NCT02812420","phase":"EARLY_PHASE1","title":"Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-03-07","conditions":"Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant","enrollment":54},{"nctId":"NCT04005690","phase":"EARLY_PHASE1","title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2019-08-01","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":90},{"nctId":"NCT04395079","phase":"PHASE2","title":"Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-08-07","conditions":"Metastatic Malignant Female Reproductive System Neoplasm, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm","enrollment":9},{"nctId":"NCT07174570","phase":"PHASE2","title":"Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-01-02","conditions":"Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8","enrollment":39},{"nctId":"NCT03539822","phase":"PHASE1, PHASE2","title":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2018-10-22","conditions":"Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma","enrollment":117},{"nctId":"NCT07166406","phase":"PHASE3","title":"Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-10-07","conditions":"Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":252},{"nctId":"NCT04430452","phase":"PHASE2","title":"Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Mary Feng, MD","startDate":"2022-02-04","conditions":"Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8","enrollment":21},{"nctId":"NCT06564623","phase":"PHASE1","title":"Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-05-27","conditions":"Biliary Tract Cancers","enrollment":25},{"nctId":"NCT03249142","phase":"PHASE1, PHASE2","title":"Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2017-10-18","conditions":"Ovarian Cancer","enrollment":69},{"nctId":"NCT03911557","phase":"PHASE2","title":"Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors","status":"COMPLETED","sponsor":"John L. Villano, MD, PhD","startDate":"2019-06-08","conditions":"Tumor, Solid","enrollment":14},{"nctId":"NCT03581487","phase":"PHASE1, PHASE2","title":"Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-01","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":40},{"nctId":"NCT06058663","phase":"PHASE1","title":"Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-06","conditions":"Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8","enrollment":16},{"nctId":"NCT02938793","phase":"PHASE2","title":"Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors","status":"TERMINATED","sponsor":"Prisma Health-Upstate","startDate":"2016-12-01","conditions":"Cancer, Rare Disease","enrollment":92},{"nctId":"NCT03026062","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-05-18","conditions":"Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma","enrollment":100},{"nctId":"NCT03019003","phase":"PHASE1","title":"Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-03-20","conditions":"Head and Neck Cancer","enrollment":13},{"nctId":"NCT04605731","phase":"PHASE1","title":"Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-08-03","conditions":"BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma","enrollment":25},{"nctId":"NCT02962063","phase":"PHASE1, PHASE2","title":"Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-11","conditions":"Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT03212469","phase":"PHASE1, PHASE2","title":"A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-06-20","conditions":"Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer","enrollment":54},{"nctId":"NCT03601455","phase":"PHASE2","title":"Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-10-26","conditions":"Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8","enrollment":13},{"nctId":"NCT06710223","phase":"PHASE1","title":"Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-01-03","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT03518606","phase":"PHASE1, PHASE2","title":"Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-06-20","conditions":"Advanced Solid Tumours, Breast Cancer, Head and Neck Cancer","enrollment":126},{"nctId":"NCT03802747","phase":"PHASE1","title":"Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2019-08","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT02953457","phase":"PHASE2","title":"Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-06-29","conditions":"BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma","enrollment":40},{"nctId":"NCT04989218","phase":"PHASE1, PHASE2","title":"Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2023-01-30","conditions":"Cholangiocarcinoma","enrollment":1},{"nctId":"NCT03116529","phase":"PHASE1, PHASE2","title":"Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2017-06-21","conditions":"Soft Tissue Sarcoma","enrollment":22},{"nctId":"NCT03204812","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-14","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma","enrollment":31},{"nctId":"NCT02754856","phase":"PHASE1","title":"Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-08-29","conditions":"Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7","enrollment":24},{"nctId":"NCT03693612","phase":"PHASE1, PHASE2","title":"GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-11-26","conditions":"Neoplasms","enrollment":26},{"nctId":"NCT00378482","phase":"PHASE2","title":"A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-03-05","conditions":"Colorectal Neoplasms, Melanoma, Prostatic Neoplasms","enrollment":37},{"nctId":"NCT02352948","phase":"PHASE3","title":"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-13","conditions":"Non - Small Cell Lung Cancer NSCLC","enrollment":597},{"nctId":"NCT02535078","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma","status":"WITHDRAWN","sponsor":"Immunocore Ltd","startDate":"2015-11","conditions":"Malignant Melanoma","enrollment":""},{"nctId":"NCT03132467","phase":"EARLY_PHASE1","title":"Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":16},{"nctId":"NCT02735239","phase":"PHASE1, PHASE2","title":"Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-06-24","conditions":"Esophageal Cancer","enrollment":73},{"nctId":"NCT02762006","phase":"PHASE1","title":"Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Moshe Ornstein","startDate":"2016-12-20","conditions":"Renal Cell Carcinoma, Kidney Cancer","enrollment":29},{"nctId":"NCT03015129","phase":"PHASE2","title":"A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-01","conditions":"Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma","enrollment":80},{"nctId":"NCT03618134","phase":"PHASE1, PHASE2","title":"Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-10-04","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":19},{"nctId":"NCT03452332","phase":"PHASE1","title":"Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-07-18","conditions":"Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma","enrollment":20},{"nctId":"NCT03522584","phase":"PHASE1, PHASE2","title":"Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-05-17","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":6},{"nctId":"NCT03373760","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2017-11-30","conditions":"Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7","enrollment":67},{"nctId":"NCT02154490","phase":"","title":"Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2014-07-08","conditions":"Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7","enrollment":1864},{"nctId":"NCT04107168","phase":"","title":"Microbiome Immunotherapy Toxicity and Response Evaluation","status":"UNKNOWN","sponsor":"CCTU- Cancer Theme","startDate":"2020-07-08","conditions":"Melanoma, Renal Cancer, Lung Cancer","enrollment":1800},{"nctId":"NCT03202758","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC","status":"COMPLETED","sponsor":"Centre Georges Francois Leclerc","startDate":"2017-08-29","conditions":"Colorectal Cancer Metastatic","enrollment":57},{"nctId":"NCT03982173","phase":"PHASE2","title":"Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors","status":"WITHDRAWN","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2020-09","conditions":"Metastatic Colorectal Cancer, Triple Negative Breast Cancer, Prostate Adenocarcinoma","enrollment":""},{"nctId":"NCT03164772","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2017-12-20","conditions":"Metastatic Non-small Cell Lung Cancer, NSCLC","enrollment":61},{"nctId":"NCT02626130","phase":"EARLY_PHASE1","title":"Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-03-30","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer AJCC v7","enrollment":29},{"nctId":"NCT02536794","phase":"PHASE2","title":"MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-01-14","conditions":"Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":30},{"nctId":"NCT02794883","phase":"PHASE2","title":"Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-11-01","conditions":"Malignant Glioma, Recurrent Glioblastoma","enrollment":36},{"nctId":"NCT02551159","phase":"PHASE3","title":"Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10-15","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":823},{"nctId":"NCT02701400","phase":"PHASE2","title":"Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-04-14","conditions":"Recurrent Small Cell Lung Carcinoma","enrollment":18},{"nctId":"NCT03081923","phase":"PHASE2","title":"Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors","status":"TERMINATED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2017-02-01","conditions":"Germ Cell Tumor","enrollment":36},{"nctId":"NCT02311361","phase":"PHASE1, PHASE2","title":"Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-25","conditions":"Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas","enrollment":65},{"nctId":"NCT03144778","phase":"PHASE1","title":"Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-12","conditions":"Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7","enrollment":39},{"nctId":"NCT03430466","phase":"PHASE2","title":"Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Kyoto Breast Cancer Research Network","startDate":"2017-06-22","conditions":"Breast Cancer","enrollment":1},{"nctId":"NCT01103635","phase":"PHASE1","title":"Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2010-02","conditions":"Recurrent Melanoma, Stage IV Melanoma","enrollment":25},{"nctId":"NCT02261220","phase":"PHASE1","title":"A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2014-10-13","conditions":"Advanced Solid Tumors","enrollment":380},{"nctId":"NCT04274816","phase":"PHASE1","title":"Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma","status":"COMPLETED","sponsor":"A.J.M. van den Eertwegh","startDate":"2012-07-10","conditions":"Cutaneous Melanoma","enrollment":13},{"nctId":"NCT03005002","phase":"PHASE1","title":"Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2017-06-28","conditions":"Metastatic Carcinoma in the Liver, MLH1 Gene Mutation, MSH6 Gene Mutation","enrollment":9},{"nctId":"NCT00702923","phase":"PHASE1","title":"CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2008-07","conditions":"Prostate Cancer","enrollment":12},{"nctId":"NCT00880854","phase":"PHASE1","title":"Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2009-06","conditions":"Bladder Cancer","enrollment":""},{"nctId":"NCT02000947","phase":"PHASE1","title":"A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2013-10-25","conditions":"NSCLC, Non-small Cell Lung Cancer, Lung Cancer","enrollment":459},{"nctId":"NCT02868632","phase":"PHASE1","title":"Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2016-08-07","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT02549651","phase":"PHASE1","title":"MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2016-07-13","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":32},{"nctId":"NCT03150836","phase":"PHASE2","title":"Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer","status":"WITHDRAWN","sponsor":"Terence Friedlander, MD","startDate":"2017-10-01","conditions":"Bladder Cancer","enrollment":""},{"nctId":"NCT00610857","phase":"PHASE2","title":"Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma","status":"COMPLETED","sponsor":"Ahmad Tarhini","startDate":"2006-11","conditions":"Melanoma","enrollment":37},{"nctId":"NCT01655888","phase":"PHASE2","title":"The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Senese","startDate":"2012-07","conditions":"Malignant Mesothelioma","enrollment":29},{"nctId":"NCT01649024","phase":"PHASE2","title":"A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Universitaria Senese","startDate":"2009-05","conditions":"Malignant Mesothelioma","enrollment":29},{"nctId":"NCT00257205","phase":"PHASE3","title":"CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-03","conditions":"Melanoma","enrollment":655},{"nctId":"NCT00431275","phase":"PHASE1","title":"Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-06","conditions":"Melanoma","enrollment":85}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"tremelimumab (anti-CTLA4)","genericName":"tremelimumab (anti-CTLA4)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tremelimumab is an anti-CTLA4 monoclonal antibody that blocks the CTLA-4 receptor, enhancing T-cell activation and proliferation. Used for Metastatic melanoma, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}